Adagio Medical Reports Second Quarter 2026 Results
Adagio reported a Q2 net loss of $6.7 million, or $(0.30) per share, with revenue remaining nil due to a pause in commercial activity in Europe. The company achieved key clinical milestones, submitting a PMA application to the FDA for its vCLAS Ventricular Ablation System and presenting pivotal data from the 209-patient FULCRUM-VT trial showing 84% freedom from ICD shock.
Key figures
- Revenue
- 0
- Net loss
- 6717000
- Rd expenses
- 2450000
- Cash balance
- 7740000
- Sga expenses
- 2484000
- Fulcrum vt patients
- 209
- Major adverse events
- 2.4%
- Freedom from icd shock
- 84%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.